A survey of susoctocog alfa for acquired hemophilia A
Part of Blood & lymphatic clinical trials.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with acquired hemophilia A
- You must have been treated with susoctocog alfa
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
This study is tracking how well Alhemo works in people with hemophilia A or B who have developed inhibitors (antibodies that block treatment). It is for patients of any age who have already started taking Alhemo as part of their regular care.
This trial will track how well Alhemo works and how safe it is for people with hemophilia A or B in everyday use. If you are 12 or older and your doctor has already decided to start you on Alhemo, this study will collect information to help doctors better understand the medicine's real-world benefits and risks.
This study looks at how safe and effective Octocog alfa (a Factor VIII medicine) is for treating sudden bleeds in adults with severe hemophilia A in India. It is for people who already have experience with Factor VIII products and are not on regular preventive treatment.
This trial studies whether a CD38-targeting antibody together with corticosteroids can improve outcomes in acquired hemophilia A. It is an “exploratory” Phase 4 study, meaning the goal is to learn more about safety and effectiveness in real-world patients.
This study provides continued access to the clotting factor treatment efanesoctocog alfa for people who have already been getting it in a previous trial. It helps ensure you can keep using the medicine if it is working for you.
Hear when a new Acquired Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.